Evidence map›Paper›PMID 42088937›Full record

ArticleThe journal of allergy and clinical immunology. Global2026

Tolerance induction for EGFR TKI hypersensitivity in lung cancer: Case report and review.

Mizuha Haraguchi Hashiguchi, Takeya Adachi, Masato Asaoka, Tamaki Ito, Sachiko Kaburagi, Junko Kagyo, Utako Okata-Karigane, Chiaki Takahashi, Umi Tahara, Suzuyuki Yoneda and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mizuha Haraguchi HashiguchiKeiyu Hospital, Kanagawa, Japan.
Takeya AdachiAllergy Center, Keio University Hospital, Tokyo, Japan.
Masato AsaokaKeiyu Hospital, Kanagawa, Japan.
Tamaki ItoAllergy Center, Keio University Hospital, Tokyo, Japan.
Sachiko KaburagiAllergy Center, Keio University Hospital, Tokyo, Japan.
Junko KagyoKeiyu Hospital, Kanagawa, Japan.
Utako Okata-KariganeAllergy Center, Keio University Hospital, Tokyo, Japan.
Chiaki TakahashiAllergy Center, Keio University Hospital, Tokyo, Japan.
Umi TaharaAllergy Center, Keio University Hospital, Tokyo, Japan.
Suzuyuki YonedaKeiyu Hospital, Kanagawa, Japan.
Katsunori MasakiAllergy Center, Keio University Hospital, Tokyo, Japan.
Koichi FukunagaAllergy Center, Keio University Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report highlights the successful use of oral desensitization to manage delayed-type hypersensitivity to afatinib, enabling continuation of treatment for epidermal growth factor receptor-mutated non-small cell lung cancer. In the absence of standardized protocols, it offers valuable insights for managing similar clinical challenges.

Indexed as

desensitizationEGFR TKIshypersensitivityNSCLCTolerance induction

Identifiers

PMID42088937
PMCPMC13138182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.